Validation of new ESPGHAN diagnostic criteria for celiac disease

s / Digestive and Liver Disease 45 (2013) e263–e311 e295 Conclusions: The association of s-ATI with trough s-IFX levels and response to therapy has been inconsistent due to a difficulty of standardization of methods of measurement of serum IFX or antidrug antibodies. There are lack data in pediatric population. Combined measurements of IFX and ATI using our cut-off levels has provided high accuracy for discriminating between responder and not-responder patients. The presence of detectable drug in the serum typically impairs the performance of a solid-phase enzymelinked immunosorbent assay (ELISA) andwestern blot.With classic ELISA, antibodies remainundetectable as long as thedrug is present in the blood. The type of detection assays also affects the reported incidence of ATIs. Our method is rapid, accurate and reproducible even if it is necessary to validate it on a larger population. Immunogenicityof IFX is apotentialmajor limitationof this class of drugand for clinicians, the loss of clinical remission due to immunogenicity is a important target especially in pediatric population.